评估 LivPhcD 胶囊在 NAFLD 受试者中的疗效和安全性
评估 LivPhcD 胶囊对 NAFLD 受试者疗效和安全性的多中心、随机、双盲、安慰剂对照研究
Non-alcoholic fatty liver disease (also called NAFLD) is a disease in which excessive fat accumulates in the liver of a patient without a history of alcohol abuse. Early-stage NAFLD does not usually cause any harm but nonalcoholic steatohepatitis (NASH) can lead to serious liver damage, including fibrosis or cirrhosis. Nearly 25% of the world's population is affected by NAFLD.
There are no FDA-approved medications for the treatment of NAFLD currently and although lifestyle modifications with appropriate diet and exercise have been shown to be beneficial, this has been difficult to achieve and sustain for the majority of patients.
LivPhcD™ capsule have shown hepatoprotective effects in both animal and human data. This study aims to investigate the effects of LivPhcD™ capsule in hepatocellular lipid content using Fibroscan.
研究概览
地位
条件
研究类型
注册 (实际的)
阶段
- 不适用
联系人和位置
学习地点
-
-
Not Required For This Country
-
Taipei、Not Required For This Country、台湾、221
- National Taiwan University Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Male or female between 20 and 75 years of age.
- Capable of giving written informed consent and able to effectively communicate with the investigator and study personnel.
- Has a body mass index (BMI) ≥20 kg/m^2 and ≤50 kg/m^2 and stable weight for the past 3 months
- CAP ≥ 238 db/m
- Fibro scan (transient elastography) F0~F3
Exclusion Criteria:
- Pregnant or breastfeeding or planning to become pregnant or unwilling to use an acceptable contraceptive method to avoid pregnancy during the study period
- Type 1 diabetes mellitus.
- History of other causes of chronic liver disease [autoimmune, primary biliary cirrhosis, HBV (HBsAg positive) and HCV, Wilson disease, alpha-1-antitrypsin deficiency, hemochromatosis etc.
- Use of medications that could induce steatosis, such as estrogen or other hormonal replacement therapy, amiodarone, methotrexate, tamoxifen, raloxifene, pharmacological doses of oral glucocorticoids (≥10 mg per day of prednisone or equivalent), or chloroquine.
- Use of vitamin E (doses ≥800 IU/dy) or pioglitazone or SGLT2 inhibitor or GLP-1 agonists any FDA-approved drug for NASH to be approved during the study.
- Has significant systemic or major illnesses other than liver disease, ex: recent events (≤6 months before study entry) of congestive heart failure, unstable coronary artery disease, serious COPD, renal failure and need hemodialysis, stroke, transient ischemic attack, or organ transplantation
- Known alcohol abuse or alcohol use disorder (>20 g/day for women; >30 g/day for men)
- Has the abnormal data including: fasting TG >400 mg/dL ; ALT or GGT>5.0 x ULN;Bilirubin >2 x ULN,unless due to an alternative etiology such as Gilbert's syndrome; INR ≥1.3; Albumin < LLN; Platelet <0.95x LLN
- Subjects with hemoglobin A1c (HbA1c) >8.5% within 3 months before study entry
- Plan to have major surgery during the study period (bariatric surgery, biliary diversion surgery)
- Participation in any other investigational clinical trial within 30 days of entry to this protocol(including drugs, medical devices, novel medical technologies, food, and lifestyle interventions affecting diet, exercise, and circadian rhythm investigational clinical trial.);
- History of HIV
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
安慰剂比较:Placebo
Placebo without active ingredient |
Placebo matching LivPhcD cap. |
|
有源比较器:2 cap.LivPhcD/per day
515mg/LivPhcD cap. 2 cap./per day |
2 caps. LivPhcD cap. after meal, once a day |
|
有源比较器:4 cap.LivPhcD/per day
515mg/LivPhcD cap. 4 cap./per day, BID |
4 caps. LivPhcD cap. after meal, BID |
|
有源比较器:6 cap.LivPhcD/per day
515mg/LivPhcD cap. 6 cap./per day, TID |
6 caps. LivPhcD cap. after meal, TID |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Reduction of Liver Fat
大体时间:36 weeks
|
Between group difference in the proportion of patients with ≥ 10% reduction of baseline of liver fat by CAP(Controlled Attenuation Parameter) |
36 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in liver fat at least 30% reduction
大体时间:24 weeks and 36 weeks
|
Between group difference in the proportion of patients with ≥ 30% reduction of baseline of liver fat by CAP |
24 weeks and 36 weeks
|
|
Change in liver fat at least 1 stage reduction
大体时间:24 weeks and 36 weeks
|
Between group difference in the proportion of patients with 1 stage reduction of baseline of liver fat by CAP |
24 weeks and 36 weeks
|
|
Change in liver fat
大体时间:24 weeks and 36 weeks
|
Between group difference in mean change of liver fat by CAP |
24 weeks and 36 weeks
|
|
Stable in liver fat
大体时间:24 weeks and 36 weeks
|
Between group difference in the proportion of patients with stable of baseline of liver fat by CAP |
24 weeks and 36 weeks
|
|
Change in liver fibrosis at least 10% reduction
大体时间:24 weeks and 36 weeks
|
Between group difference in the proportion of patients with ≥ 10% reduction of baseline of liver fibrosis by Fibroscan |
24 weeks and 36 weeks
|
|
Change in liver fibrosis at least 1 stage reduction
大体时间:24 weeks and 36 weeks
|
Between group difference in the proportion of patients with 1 stage reduction of baseline of liver fibrosis by Fibroscan |
24 weeks and 36 weeks
|
|
Stable in liver fibrosis
大体时间:24 weeks and 36 weeks
|
Between group difference in the proportion of patients with stable reduction of baseline of liver fibrosis by Fibroscan |
24 weeks and 36 weeks
|
|
Change in liver fibrosis
大体时间:24 weeks and 36 weeks
|
Between group difference in mean change of FIB-4 |
24 weeks and 36 weeks
|
|
Change in ALT
大体时间:24 weeks and 36 weeks
|
Between group difference in mean change or in the proportion of patients of ALT |
24 weeks and 36 weeks
|
|
Change in AST
大体时间:24 weeks and 36 weeks
|
Between group difference in mean change or in the proportion of patients of AST |
24 weeks and 36 weeks
|
|
Change in GGT
大体时间:24 weeks and 36 weeks
|
Between group difference in mean change or in the proportion of patients of GGT |
24 weeks and 36 weeks
|
|
Change in AP
大体时间:24 weeks and 36 weeks
|
Between group difference in mean change or in the proportion of patients of AP |
24 weeks and 36 weeks
|
|
Change in Bilirubin
大体时间:24 weeks and 36 weeks
|
Between group difference in mean change or in the proportion of patients of Bilirubin |
24 weeks and 36 weeks
|
|
Change in Triglyceride
大体时间:24 weeks and 36 weeks
|
Between group difference in mean change or in the proportion of patients of Triglyceride |
24 weeks and 36 weeks
|
|
Change in Total Cholesterol
大体时间:24 weeks and 36 weeks
|
Between group difference in mean change or in the proportion of patients of Total Cholesterol |
24 weeks and 36 weeks
|
|
Change in HDL-C
大体时间:24 weeks and 36 weeks
|
Between group difference in mean change or in the proportion of patients of HDL-C |
24 weeks and 36 weeks
|
|
Change in LDL-C
大体时间:24 weeks and 36 weeks
|
Between group difference in mean change or in the proportion of patients of LDL-C |
24 weeks and 36 weeks
|
|
Change in TNF-α
大体时间:24 weeks and 36 weeks
|
Between group difference in mean change or in the proportion of patients of TNF-α |
24 weeks and 36 weeks
|
|
Change in C-Reactive Protein
大体时间:24 weeks and 36 weeks
|
Between group difference in mean change or in the proportion of patients of C-Reactive Protein |
24 weeks and 36 weeks
|
|
Change in Albumin
大体时间:24 weeks and 36 weeks
|
Between group difference in mean change or in the proportion of patients of Albumin |
24 weeks and 36 weeks
|
|
Occurrence of adverse events and serious adverse events
大体时间:24 weeks and 36 weeks
|
Between group difference in the occurrence of adverse events and serious adverse events. |
24 weeks and 36 weeks
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.